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Background
With progress in molecular biology, the presence of telom-
erase activity, P53 mutation and Ki-ras codon 12 point
mutation has been reported in malignant tumours of the
liver, pancreas and biliary tree. The purpose of this paper
is to clarify the clinical implications of finding these three
biomarkers in the peripheral blood of affected patients.
Methods
Telomerase activity, P53 mutation, and Ki-ras codon 12
point mutation in the peripheral blood were examined
among 86 patients with hepato pancreato biliary disease,
both benign and malignant, and the results were compared
with clinical findings.
Results
Of 20 patients with benign conditions , only one patient
with intraductal papillary adenoma showing severe dyspla-
sia exhibited a biomarker (telomerase activity) in the
peripheral blood. In total, there were 66 patients with var-
ious HPB carcinomas. Of 56 cancer patients studied pre-
operatively, 16 were positive for more than one biomarker,
13 were positive for telomerase activity, 4 for P53 muta-
tion (three at exon 7 and another at exon 8), and 2 for Ki-
ras codon 12 point mutation (both in the second letter).
Twelve of the 16 biomarker-postiive patients had stage IV
disease as opposed to 23 of 40 biomarker-negative
patients. The resectability rate of the cancer was 38% in
positive patients and 50% in negative patients.The one-year
survival rate after resection was zero in positive patients
and 15% in negative patients, but the difference was not
significant (P = 0.65). Of 32 patients with liver metastasis at
the time of the molecular examination, eight were positive
and 24 negative. Of 34 patients without liver metastasis,
nine were positive and 25 negative. The development of
subsequent liver metastases in those without them at the
start was not significantly different in those with and with-
out biomarkers (56 vs 36%: P = 0.31).
Conclusions
The three novel biomarkers of the peripheral blood
seemed to be of little value for screening of early malig-
nant HPB neoplasms but may help to predict liver
metastasis.
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Introduction
With the recent advances in molecular biology, new bio-
markers of cancer have been reported, including telomerase
activity, Ki-ras codon 12 point mutation and P53 mutation.
Micrometastasis or circulating cancer cells have been sug-
gested in patients with carcinoma of the colon, breast, pan-
creas and other organs using these biomarkers. The ras gene
family encodes 21-kDa membrane-bound proteins involved
in signal transduction. The mutation in Ki-ras oncogene
that leads to the activation of GTP/GDP binding protein
(RAS p21) involves the 12th codon. These mutations
almost exclusively involve a single base pair substitution,
which produces an amino acid substitution from glycine
to aspartic acid, valine, or arginine. Ki-ras codon 12 point
mutaton is frequently seen in carcinoma of the gallbladder
[1], bile duct [1], intrahepatic duct [2] and pancreas [3].
The P53 gene is located at 17p 13.3 and is a common
tumour suppressor gene seen in human carcinomas. This
gene is frequently mutated in a variety of human cancers,
the incidence being 50% for pancreatic carcinoma [4–6]
and 30% for gallbladder carcinoma [7]. The presence of
mutations is detected in exon 5 through 8, which occupies
86% of all mutations reported for the P53 gene [5]. Telom-
erase is an enzyme that contains an RNA template com-
plementary to (GGTTAG) repeats and is believed to be
involved in the de novo synthesis of GGTTAG telomeric
DNA onto chromosomal ends. Telomerase is important to
maintain continuous cell proliferation, by overcoming the
end-replication problem, and the activity is seen in more
than 80% of various malignant neoplasms, including 95%
of pancreatic carcinomas [8] and about 85% of hepato-
cellular carcinomas [9].
The materials used in the vast majority of such
papers are tumour tissues, while minimally invasive or
non-invasive sampling of urine, stool or blood is more
important in the clinical fields. Very few studies have
employed a combination biomarker assay. The present
study comprised a combination analysis of telomerase
activity, Ki-ras codon 12 point mutation and P53 muta-
tion of the peripheral blood in patients with HPB dis-
eases, both benign and malignant, to determine the
clinical implications of these three biomarkers.
Materials and methods
Tissue samples and DNA extraction
The series included 86 Japanese patients with various HPB
diseases treated in the Department of Surgery I, Kyushu
University Faculty of Medicine, Fukuoka, Japan, between
March 1994 and May 1998; three hepatolithiasis, five
hepatocellular carcinoma, five cholangiocarcinoma, three
metastatic liver cancer, one choledocholithiasis, 12 bile
duct carcinoma, 13 gallbladder carcinoma, two ampullary
carcinoma, six pancreatitis, eight intraductal papillary
mucinous adenoma, two islet cell adenoma and 26 pancre-
atic carcinoma. When more than one molecular marker
was positive, the patient was regarded as biomarker-
positive, and the others as biomarker-negative.
The diagnosis of malignancy was obtained by cytol-
ogy and/or histopathology. Fifty-five patients underwent
laparotomy, and in these, the peripheral blood was
sampled after the patient was anaesthetised. In the 31
non-laparotomy patients, the peripheral blood was
obtainable in the surgical ward. In 47 of the 86
patients, tumour samples obtained intraoperatively were
also examined for the biomarkers. The staging of malig-
nant conditions was determined by the cancer staging
manual of the American Joint Committee on Cancer
[10]. Follow-up imaging of the liver was obtainable
within 6 months of operation in 27 patients who
underwent surgical resection for HPB malignancy. The
clinical follow-up after the surgical resection was updated
as of September 1998.
The blood samples were stored with an RNAase
inhibitor at 24°C. Genomic DNA was extracted by pro-
teinase K digestion and phenol/chloroform extraction using
the method of Sambrook et al. [11] for the Ki-ras codon 12
point mutation assay and P53 mutation examination.
Duplicate assays were performed.
Primers for Ki-ras codon 12 point mutation
and P53 mutation
In the examination of Ki-ras codon 12 point mutation, we
used a mixture of three synthetic oligonucleotides which
corresponded to the possible variants of the first nucleotide
or three oligonucleotides which corresponded to the three
variants of the second nucleotide of codon 12 of the Ki-ras
gene for one of the primers for polymerase chain reaction
(PCR). Primers used for PCR were synethesized in an ABI
DNA synthesizer model 392 (Applied Biosystems, Foster
City, CA, USA). The two sets of primers are as follows:
set 1: 5’>ACTTGTGGTAGTTGGAGCTC,
5’>ACTTGTGGTAGTTGGAGCTT,
5’>ACTTGTGGTAGTTGGAGCTA
and set 2: 5’>CTTGTGGTAGTTGGAGCTGC,
5’>CTTGTGGTAGTTGGAGCTGT and
5’>CTTGTGGTAGTTGGAGCTGA.
In the analysis of P53 mutation, oligonucleotides were
synthesized as primers for PCR based on the published P53
gene sequence for each region flanking the intron/exon 5 to
8 [12]. The designations and sequences for each primer
were as follows:
EX-05f, 5’-TCTGTCTCCTTCCTCTTCCT-3’:
EX-05r, 5’-TCTCCAGCCCCAGCTGCT-3’:
EX-06f, 5’-TGATTCCTCACTGATTGCTCT-3’:
EX-06r, 5’-GAGACCCCAGTTGCCAAACC-3 ’:
EX-07f, 5’-TCTTGGGCCTGTGTTATCTC-3’:
EX-07r, 5’-AGGGTGGCAAGTGGCTCC-3’:
EX-08f, 5’-GCTTCTCTTTTCCTATCCTGA-3’:
and EX-08r, 5’-CGCTTCTTGTCCTGCTTGC-3’.
The number in each designation indicates the region of
the exon of the P53 gene subjected to examination by
polymerase chain reaction PCR-fluorescence-based single-
strand-conformation-polymorphis m (PCR-FSSCP) analy-
sis. ‘f ’ and ‘r’ indicate forward and reverse primers for
each region. All the primers were labelled at their 5’ ends
with fluorescein derivatives by the Fluore prime method
(Pharmacia Biotech Co. Ltd, Tokyo, Japan).
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Polymerase chain reaction for Ki-ras codon 12
point mutation and P53 mutation
Ki-ras codon 12 point mutation
PCR was performed in 40 cycles of 0.5 min at 95°C, 2 min
at 53°C. and 2 min at 70°C, as described by Baker et al.
[13]. Mutant-allele-specific amplification (MASA) was
performed in 32 cycles of 0.5 min at 95°C, 2 min at 59°C
or 60°C, and 2 min at 70°C, by the modified Takeda’s
method [14] except for the absence of dimethyl sulfoxide
(DMSO). PCR products (5 l l) were electrophoresed in a
3% agarose gel containing 0.5 l g/ml ethidium bromide.
Ethidium-bromide staining of PCR products was performed
for detection of point mutations in the Ki-ras gene and was
visualised under ultra-violet light. The mutant allele spe-
cific amplification method employed could detect 5 cancer
cells among 104 normal lymphocytes [14].
PCR-FSSCP analysis for P53 mutation
One hundred ng of genomic DNA was amplified in a total
volume of 50 µl in the buffer containing 100 l M concen-
trations of dATP, dCTP, dGTP and dTTP, and 0.125 units
of Amplitaq (a kind of Taq DNA polymerase) in the buffer
recommended for the enzyme, using primers labelled at
their 59 ends with fluorescein. The PCR products were
diluted 50 times by a stop solution (Pharmacia Biotech Co.
Ltd, Tokyo, Japan), heated at 95°C for 5 min and then
placed on ice for 5 min. Then 4 l l of this solution was
applied to each lane of FSSCP gel fitted to an ALF II
automated DNA sequencer (Pharmacia Biotech Co. Ltd,
Tokyo, Japan). The FSSCP gel used was 7% polyacrylamide
gel containing 5% glycerol. Electrophoresis was performed
at 30 W for 3 to 4 h, depending on the length of the ampli-
fied nucleotide. The temperature of the gel was kept at
25°C with a built-in water jacket connected to an external
thermostat-regulated water circulation system. With PCR-
FSSCP analysis of P53 mutation, one cancer cell among
102 normal lymphocytes could be detected.
Telomerase activity assay
For telomerase activity assay, TRAP-eze™ kit (Oncor Inc.,
Gaithersburg, MD, USA) was utilised. The kit provided
each reagent necessary for the telomeric repeat amplifica-
tion protocol (TRAP) assay with a primer mixture that
includes the RP primer, K1 primer and a TSK 1 template
that serves as the 36 bp internal standard. In addition, the
kit provided a control cell pellet of 106 telomerase positive
cells and a TRS8 control template, which gave a telom-
erase ladder in the presence of Taq DNA polymerase and
the TS and RP primers. 0.5 l g of sample protein was
applied to the reaction. The telomerase extension was car-
ried out at room temperature for 20–30 minutes followed by
a hot start at 94°C for 3 minutes. A three-step PCR proto-
col was used (94°C for 30 seconds, 56°C for 30 seconds,
72°C for 60 seconds for 30 cycles). The PCR product was
electrophoresed on 12.5% non-denaturing, 1.5 mm thick
acrylamide gel (10 3 10 cm) and was run on 0.5 3 TBE
(50 mM Tris-borate (pH 8.3), 1 mM EDTA) at 30 mA until
the bromophenol blue just ran off the gel (approximately
2 hours). The PCR products were stained with SYBR™
green staining (FMC BioProducts, Rockland, ME, USA).
The gels were documented using the FMBIO fluorescence
image analyser (Hitachi Software Engineering Co. Ltd,
Tokyo, Japan).
Statistical analysis
The distribution of patients was measured by the
Chi-square test. Sensitivity, specificity, and positive and
negative predictive values were calculated. One-year cumu-
lative survival rate was calculated, and the difference
between the survival rates was measured by log-rank test.
Results
Biomarkers in the peripheral blood
Among 10 patients with benign inflammatory diseases, all
three biomarkers were negative (Table 1). Among 10
patients with a benign neoplasm, only one with intraductal
papillary adenoma and severe dysplasia showed telomerase
activity in the peripheral blood.
Of 56 preoperative patients with HPB carcinomas, 16
patients were positive for more than one biomarker in the
peripheral blood; 13/51 showed telomerase activity (Figure
1), 4/55 showed a P53 mutation (three at exon 7 and
another at exon 8) (Figure 2), and 2/49 showed a Ki-ras
codon 12 point mutation (both in the second letter) (Fig-
ure 3). Telomerase activity was positive in the blood of 3/10
patients with liver cancer, 4/20 with bile duct cancer and
6/21 with pancreatic cancer. P53 mutation was present in
2/12 patients with liver cancer, 0/20 with bile duct cancer,
and 2/23 with pancreatic cancer. Ki-ras codon 12 point
mutation was evident in 0/11 with liver cancer, 1/18 with
biliary tract cancer and 1/21 with pancreatic cancer. In 47
of the 86 patients, both the tissue samples and peripheral
blood were examined for the biomarkers (Table 2). In 15 of
these 47, biomarkers were positive in tumour tissue sample,
and in 8 of them biomarkers were positive in peripheral
blood. In only two patients were biomarkers positive both
in the tumour tissue and the blood; K-ras codon 12 point
mutation was positive in the tumour tissue and telomerase
activity in the blood.
Of the 56 preoperative patients with HPB cancer, the
16 who were biomarker-positive, included two in stage I,
two in stage II and 12 in stage IV (Table 3). The other 40
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Table 1. Telomerase activity, P53 mutation and Ki-ras codon 12 point mutation of the peripheral blood in 86 patients with HPB disease
Telomerase P53 Ki-ras codon 12 Molecular
activity mutation point mutation abnormality
Liver
Hepatolithiasis – 0/3 0/1 0/3
HCC 1/5 2/5 (Exon 7) 0/5 2/5
CC 1/3 0/4 0/4 1/5
Metastatic cancer 1/2 0/3 0/2 1/3
Biliary tract
Choledocholithiasis – 0/1 – 0/1
Bile duct cancer 4/12 (1/2) 0/12 (0/2) 0/10 (0/1) 4/12 (1/2)
Gallbladder cancer 1/13 (0/5) 0/13 (0/5) 1/11 (2nd letter) (0/5) 2/13 (0/5)
Ampullary cancer 0/2 0/2 0/2 0/2
Pancreas
Pancreatitis 0/5 0/6 0/3 0/6
Intraductal papillary
mucinous adenoma 1/7 0/8 0/7 1/8
Islet cell adenoma 0/2 0/1 0/1 0/2
Pancreatic cancer 6/24 (0/3) 2/26 (Exon 7,8) (0/3) 1/24 (2nd letter) (0/3) 7/26 (0/3)
HCC: hepatocellular carcinoma, CC: cholangio carcinoma, ( / ): patients after resection of HPB cancer
Figure 1. Telomerase activity examined by the TRAP-eze™ kit M: size marker
pUC19/Mspl, Lane 1: bile duct carcinoma (negative), Lane 2: pancreatic carci-
noma (positive), Lane 3: pancreatic carcinoma (negative), Lane 4: gallbladder
carcinoma (negative), Lane 5: positive control, Lane 6: negative control, Lane 7:
TSR8 control (0.1 amole), Lane 8: TSR8 control (0.2 amole). Band in lane 2,
which is stronger than lane 7 (positive control) is judged as positive for telom-
erase activity. Bands in lanes 1, 3, 4, which are faintly present but weaker than
lane 7, are judged as negative for telomerase activity.
Figure 2. P53 mutation (Exon 7). Pancreatic carcinoma (upper curve, posi-
tive). Upper curve shows peaks (arrows) which are not seen in the lower curve
representing healthy controls (negative control) and indicate P53 mutation (PCR-
FSSCP). Pancreatitis (middle curve, negative).
who were biomarker-negative included one in stage I, four
in stage II, 12 in stage III and 23 in stage IV. The positive
biomarker in the peripheral blood of the two patients in
stage I pancreatic cancer was telomerase activity. Resection
was performed in 26 of the 56 cancer patients. The
resectability rate in biomarker-positive patients was 38%
(6/16) and in biomarker-negative patients 50% (20/40)
(Table 4). The sensitivity of the biomarkers to non-
resectability was 33%, specificity 77%, positive predictive
value 63% and negative predictive value 50%.
The one-year survival rate after surgical resection in 20
biomarker-negative patients was better than that of seven
biomarker-positive patients (15% vs 0%), but the differ-
ence was not statistically significant (P = 0.65).
Biomarkers in the peripheral blood and liver
metastasis
Of 10 patients studied after resection of HPB cancer, one
(10%) was positive for telomerase activity but free from liver
metastasis and the other nine biomarker-negative patients
included eight with liver metastasis (Table 3). The absence
of biomarkers indicated the presence of liver metastasis after
resection, although the number of patients examined was
small (P = 0.0350). Of the total 66 patients with HPB can-
cer, liver metastasis was present at the time of molecular
examination in 32 and absent in 34. Among the 32 patients
with liver metastasis at the time of the molecular examina-
tion, more than one biomarker was positive in eight (25%)
(Table 5). Among the other 34 patients without liver metas-
tasis at the time of the molecular examination, more than
one biomarker was positive in nine (26%). The sensitivity of
the biomarkers to liver metastasis at the time of molecular
examination was 25%, specificity 69%, positive predictive
value 47% and negative predictive value 51%. Of the 34
patients without liver metastasis at the time of molecular
examination, 14 patients developed liver metastasis within
six months of the examination and the other 20 did not.
Five of the nine biomarker-positive patients without liver
metastasis at the time of the examination subsequently
developed liver metastasis, as opposed to 9 of 25 patients
who were negative for biomarkers (Table 6). The sensitivity
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Figure 3. Ethidium-bromide staining of PCR products for detection of Ki-ras
codon 12 point mutation (second letter). Lane 1: size marker pUC19/Mspl,
Lanes 2–4: healthy control (negative control), Lanes 5–7: positive control (5 3
105 copies (5), 5 3 10
2 (6), 5 3 10
1 (7)), Lane 8: gallbladder carcinoma (pos-
itive), Lane 9: hepatocellular carcinoma (negative), Lane 10: pancreatic carci-
noma (positive), Lane 11: ampullary carcinoma (negative), Lane 12: metastatic
liver tumour (negative), Lane 13: chronic pancreatitis (negative), Lane 14: islet
cell adenoma (negative). Bands in lanes 8 and 10, which are stronger than lane
7 (positive control, 5 3 10
1 copies), are judged as positive for Ki-ras codon 12
point mutation.
Table 2. Biomarkers in tumour tissue samples and peripheral blood
Tumour tissue
Positive Negative
Positive 2 6
Peripheral
blood
Negative 13 26
Statistical analysis P = 0.6451
Table 3. Comparison of AJCC staging before resection, liver metastasis after resection and biomarkers of the peripheral blood in 66 patients
with HPB cancer
Staging before resection Liver metastasis Liver metastasis
(AJCC Stage) after resection after resection
I II III IV Present Absent Se Sp PPV NPV
Positive 2 0 2 12 0 1
Biomarkers 0% 50% 0% 11%
Negative 1 4 12 23 8 1
Statistic analysis
P-value P = 0.1275 P = 0.0350
Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value;AJCC:American Joint Committee on Cancer
of the biomarkers to the occurrence of liver metastasis
within six months was 35%, specificity 80%, positive
predictive value 56% and negative predictive value 64%.
Discussion
Telomerase activity, P53 mutation and Ki-ras codon 12
point mutation in the peripheral blood were examined to
clarify the clinical implications of the three biomarkers in
86 patients with HPB diseases. Of 20 patients with benign
conditions, only one (5%) with intraductal papillary ade-
noma and severe dysplasia showed a biomarker (telomerase
activity). Of 56 preoperative patients with HPB carcino-
mas, 16 patients were positive for more than one biomarker.
The biomarkers seemed to correlate with advanced stages
of HPB carcinoma but not with the resectability rate or the
one-year survival rate after surgical resection. Biomarkers
were positive in 25% of patients with liver metastasis at the
time of the molecular examination, while 56% of marker-
positive patients without initial metastasis developed clini-
cal liver metastasis within six months.
Some normal adult somatic tissues exhibit telomerase
activity, including male germ cells, the basal layer of the
epidermis, the proliferative zone of the intestine, activated
lymphocytes and blood stem cells. In addition, telomerase
activity is detectable in normal human peripheral blood
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Table 4. Molecular examination of the peripheral blood and resectability of the primary tumour in 56 preoperative patients with
malignant HPB cancer
Resectable Not resectable
Yes No Se Sp PPV NPV
Positive 6 10
Biomarkers 33% 77% 63% 50%
Negative 20 20
Statistic analysis
P-value P = 0.3968
Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value
Table 5. Presence or absence of liver metastasis at the time of the molecular examination and biomarkers of the peripheral blood in 66
patients with HPB cancer
Presence of Presence of
liver metastasis liver metastasis
Present Absent Se Sp PPV NPV
Positive 8 9
Biomarkers 25% 69% 47% 51%
Negative 24 25
Statistic analysis
P-value P = 0.8914
Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value
Table 6. Occurrence of liver metastasis and biomarkers in 34 patients without liver metastasis at the time of the molecular examination
Occurrence of Occurrence of
liver metastasis liver metastasis
Yes No Se Sp PPV NPV
Positive 5 4
Biomarkers 35% 80% 56% 64%
Negative 9 16
Statistic analysis
P-value P = 0.3067
Se: sensitivity; Sp: specificity; PPV: positive predictive value; NPV: negative predictive value
leucocytes including T cells and B cells [15–17]. This evi-
dence might suggest that telomerase activity in the periph-
eral blood produces a false positive result. However, the
telomerase activity in these cells is extremely low, being
about 1–2% of the activity found in cancer cells [18]. In the
present study, positive telomerase activity from the acti-
vated peripheral lymphocytes was eliminated to the best of
our ability. Nine patients with acute inflammatory diseases
were negative for telomerase activity in peripheral blood
(unpublished data). The TRAP-eze™ kit used in the pres-
ent series contains both negative and positive controls, a
control cell pellet of 106 telomerase positive cells and a
TRS8 control template, which give a telomerase ladder in
the presence of Taq DNA polymerase and the TS and RP
primers. We carefully evaluated the results comparing the
bands obtained with the negative and positive control
bands. Therefore, the false positivity of telomerase activity
by the peripheral lymphocytes was eliminated as far as
possible.
Although all the steps leading to cancer are not yet
known, progression to a cancerous state requires accumula-
tion of a series of genetic alterations. An emerging hypoth-
esis suggests that the upregulation or re-expression of
telomerase is critical to cancer cell growth. In contrast to
normal cells, tumour cells show no net loss of the telomere
length with cell division, suggesting that telomere stability
may be required for cells to escape replicative senescence
and proliferate indefinitely. Immortalisation may occur
through mutation of a gene in the telomerase repression
pathway, permitting the expression of telomerase and the
maintenance of telomere stability in cancer cells. Thus it is
becoming generally accepted that the upregulation or reac-
tivation of telomerase activity may be a rate-limiting, if not
critical, step required for the continuing proliferation of
cancers. In the present study of the peripheral blood,
telomerase activity was the most sensitive of the three bio-
markers. The activity was evident in 16 of the 56 preoper-
ative patients with HPB cancer but in only one of the 20
patients with benign conditions (29 vs 5%).
Interestingly, one patient with intraductal papillary
adenoma showing severe dysplasia was positive for telom-
erase activity. This case might therefore be one of intraduc-
tal papillary adenocarcinoma. Telomerase activity in this
patient might indicate cancer cells in the peripheral blood.
At present, the patient is being followed up very carefully.
Several studies demonstrate a relationship between bio-
markers and clinical outcome in certain cancers. The pres-
ence of telomerase activity has been shown to correlate
with poor clinical outcome in gastric cancer [19]. High
levels of enzyme correlate with poor clinical outcome in
neuroblastoma, whereas patients with metastatic neurob-
lastoma without telomerase activity experience sponta-
neous regression of the tumours [20]. Clinical outcome and
several prognostic indicators of breast cancer have been
shown to have a statistically significant correlation with
the level of telomerase activity [21]. High telomerase activ-
ity is detected frequently in primary non-small-cell lung
cancers that exhibit high tumour cell proliferation rates
and an advanced pathological stage [22]. The presence of
P53 mutation correlated with poor prognosis in pancreatic
carcinoma [23]. In the present series, the biomarkers were
seen in more advanced HPB carcinomas, and there was a
trend towards better survival after surgical resection in
biomarker-negative patients.
The presence of biomarkers may indicate minimal resid-
ual disease in patients undergoing surgical resection, and
their detection may be a useful surrogate end-marker for
following chemoradiation. They are examined by highly
sensitive molecular biology. It was reported that with the
application of a mutant allele specific amplification
method to examine cytokeratin, a single cancer cell could
be detected among 104 normal cells in lymph nodes.
Telomerase activity is seen in 80–90% of human cancers
and telomerase activity in the peripheral blood was studied
to determine the development of liver metastasis after sur-
gical resection. In the present series, five of nine biomarker-
positive patients developed liver metastasis, as opposed to
nine of 25 biomarker-negative patients. Thus biomarker
positivity faintly predicted liver metastasis, albeit with low
sensitivity and accuracy.
Clinical demands for biomarkers are to:
1) detect early malignant disease;
2) screen malignant disease by non-invasive or mini-
mally invasive sampling;
3) predict biological behaviour; and
4) identify an important subgroup of patients who
might benefit from post-operative adjuvant therapy.
Combination assays can be expected to compensate for low
individual sensitivity of the biomarkers, but the combina-
tion of P53 mutation or Ki-ras point mutation with telom-
erase has been reported by few other authors. In the present
series, the three biomarkers were positive in the peripheral
blood in 26% of HPB carcinoma patients. The vast major-
ity of biomarker-positive patients were positive for telom-
erase activity, and the patients with all three biomarkers
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were invariably in stage III or IV. Therefore, these three
biomarkers were not useful for screening of early HPB
cancer, but could have some value for prediction of liver
metastasis.
In conclusion, telomerase activity was the most sensi-
tive of the three biomarkers in the peripheral blood in the
patients with HPB cancer. Their presence seemed to corre-
late with advanced-stage disease but not with resectability
or clinical outcome after resection.
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